RAJASTHAN DRUGS & PHARMACEUTICALS LIMITED
(A Govt. of IndiaEnterprise)
Road No. 12, V.K.I. Area, Jaipur-302013.

PHONE NO: 0141-4035468, 4107105FAX NO: 0141-4107101
Website: www.rdpl-lindia.in e-mail: purchase@rdpl-india.in

TENDER/LL/ MATERIALS/ REF. No……../2016-2017/DATED:……..

NOTICE INVITING TENDER

Tender document is invited from eligible manufacturers for Loan licence manufacturing (Turnkey basis) of Pharmaceuticals Formulations

Due date and time for submission of Tender document:
15days from date of publication in the leading NEWS paper before 3.00pm.

RAJASTHAN DRUGS & PHARMACEUTICALS LIMITED

(A Govt. of IndiaEnterprise)
Road No. 12, V.K.I. Area, Jaipur-302013.

Tender document is invited from eligible manufacturers for Loan licence (Turnkey Basis) manufacturing of Pharmaceuticals Formulations

Rajasthan Drugs&Pharmaceuticals Ltd. Jaipur (RDPL) is a leading central Public sector enterprise (CPSE) functioning under administarative control of Department of Pharmaceuticals, Ministry of Chemicals &Fertilizers, Govt. of India, engaged in the manufacturing and marketing of life-savingdrugs.

Sealed Expression of Interest are invited from reputed and technically sound Pharmaceuticals Formulations manufacturers valid licence with GMP and meeting requirements of new schedule 'M' with minimum three years manufacturing experience with annual average turnover of last three years of Rs. 20.00 Crore to manufacture similar items as per specifications mentioned in ANNEXURE-I preferred. This will be running contract for one year. The interested party can purchase tender on any working day between 10.30 AM to 3.00 PM upto **15days from date of publication in the leading NEWS paper before 3.00pm.** by paying a fee of Rs. 1000/- or download the tender document from our website and deposit the D.D of Rs. 1000/- in favour of RDPL, Jaipur alongwith tender document. The completed offers shall be accepted up to 3.00 p.m. on **15days from date of publication in the leading NEWS paper before 3.00pm.** **and** shall be opened on the same day at 3.30 PM. The parties desiring to attend the offer opening may do so at their own cost. The manufacturere required to submit earnest money in the form of Bank Draft of **Rs. 2.0 lac** in favour of RDPL, Jaipur, which shall be returned to the unsuccessful bidder subsequently. The offers submitted without earnest money shall be rejectedout rightly. All the bidders are requested to read the terms and conditions of the Expression of Interest document very carefully and submit their offers accordingly. In case of any deviation from the tender document, terms and conditions, their offers are likely to be rejected. RDPL reserves all rights to accept or reject any of the offers in full or in part without assigning any reason.

1. **Pre- Requisite Qualifications:**

   The bidder should meet the following requirements:-

   a) Only original Manufacturers are eligible to participate for the tender.

   b) Should have minimum three years manufacturing experience and annual average three years turn over of Rs. 20.00 crores during three preceeding financial years' i.e.2013-14, 2014-15, and 2015-16.

   c) The Manufacturer should have valid manufacturing licence issued from licencing authority with revised schedule-M certificate and GMP certificate preferred.

d) The Manufacturer should have a valid GOOD MANUFACTURING PRACTICES (GMP) certificate and valid manufacturing licencing authority.

e) The Manufacturer should have two years manufacturing experience for respective product or similar products prefered.

f) The manufacturer shall submit authentic proof like balance sheet duly authenticated by Chartered Accountant year wise for 3 years and of volume of sales in terms of money both in private and Government sector.

g) The manufacturer should have capability to render services as Marketing Associate for procuring orders of Pharmaceuticals Formulations.

h) The bidder should disclose any law suits and court cases which may affect the proposed arrangement.

i) The bidder should submit list of Directors / Partners / Proprietor alongwith their addresses and copy of Article & Association.

2. **Specifications of the items & scope of work:**
The detailed specifications of the items to be manufactured on Loan Licence/ Lease along with required pack size, specifications of the containers, etc. are given in ANNEXURE-I. The quantities are required approximately in phase manners.

3. **Rates:-**

(a) The rates for supply of each item of medicines as specified in ANNEXURE-1 should be quoted separately.

(b) All the items, as mentioned in ANNEXURE-1 are required to be manufactured on Loan Licence of RDPL. RDPL shall obtain loan licence if applicable from respective Drugs Control Authorities and the tenderer will have to provide necessary assistance/ facilities, such as, storage place/obtaining wholesale licence, etc being essential requirements for obtaining loan licence under the Drugs & Cosmetic Act. The necessary production records / purchases records are required to be kept under the Drugs Act & Rules there under.

(c) The rates quoted should be on the turnkeybasis i.e. It should include the cost of raw-material, packing material, conversion cost, testing expenses, freight & forwarding charges, insurance, Excise Duty, octroi and other levies as applicable. <u>The rates quoted should be on the basis of F.O.R. RDPL works Jaipur</u> or any destination in the country as advised by the company. It should also include charges for warranty and replacements. However, Sales Tax, i.e. CST/VAT may be levied extra for which necessary declaration forms shall be provided by the company. The manufacturer shall provide complete costing of each product without which the rates are not accepted.

(d) The price shall be kept valid for a period of minimum one year from the date of signing the agreement under this contract. No other charges in addition will be payable on any account over and above the prices quoted.

(e) The rates quoted in an ambiguous manner will render the tender liable for rejection.

(f) The rates quoted by the tenderer shall remain fixed during the currency of the contract and not subject to variation on any account. Other terms of quotations not prescribed by RDPL may render the offer as rejected.

(g) Tender should be signed by Tenderer on all pages with official seal.

4. **Technical Qualifications:**

(a) The manufacturer should have well equiped of machineries, equipments to be required for manufacturing of Pharmacetucals Formulation.
(b) All the items, raw material are required to manufacturingfor RDPL must be tested before used in production.
(c) Bidder should have own Quality control section, for testing of raw material, in process and finished goods.
(d) Bidder should have the adequate facilities for store, Office, Rejected goods/ storage place for finished goods, etc. as per norms specified in Drugs & Cosmetics ACT.
(e) RDPL technical committee shall inspect the bidders manufacturing facilities to ensure competency, adequecy, suitability, systems, arrangements, procedures, practices followed in conformity with standards.

(f) Theinspection report of technical committee will be on the basisof qualification of bidders.

(g) All the items, as mentioned in ANNEXURE-Irequired to be manufactured by RDPL shall be on fixed cost basis quoted by manufacturer.The manufacturer shall ensure that manufacturing facilities shall be in running and meets the cGMP requirement. It shall also include charges for warranty and replacements. However, Sales Tax, i.e. CST/VAT may be levied as applicable as per provisions of the Act.

(h) The manufacturer should submit sample & NABL approved late reports to RDPL factory QC/QA dept. before find release of product.

(i) The bidder shall quote firm offers.Incomplete or conditional offers incorporating rate variation and force majeure clauses etc.shall not be entertained.

5. **Important Documents to be submitted along with offer:**

(a) The manufacturer shall submit certified details of manufacturing unit and production capacity and also submit details of technical personnel employed in manufacturing and testing of Pharmaceuticals Formulations.

(b) Site master plan and Site master file along with details of QC, QA and number of technical persons working need to be furnished.

(c) Latest non-conviction certificate obtained from the respective State Licencing Authority, stating that there were no market complaints against the manufacturer and the manufacturer has not been convicted under any clauses of Drugs & Cosmetics act and rules thereunder.

(d) Statement of products (with details) declared sub-standard by the State Licencing Authority during last three years with reasons and also action taken by the Licencing Authorities and subsequent steps initiated by bidder if any.

(e) Vendors list of Raw marerials& packing materials suppliers.

(f) Details of existing R/C if any with any buyers/PSUs.

(g) Installed capacity of manufacturer for last 3 year duly certified by chartered Accountants. (Unit wise).

(h) Samples for products required to be manufactured as per Annexure-I.

(i) A certified copy of audited financial statements for the last three financial years.

(j) Certified copies of latest income-tax return/tax clearance certificate.

(k) Copy of PAN card of all Directors/Partners.

(l) Details of facilities being availed from the Bank (i.e. working capital limits, etc.) along with name and address of the Bank and mode of Account being operated.

(m) The bidder shall provide attested copy of theannualSale tax statement of the preceding year.

(n) Letter of creditworthiness from the Bank.

(o) Copy of Memorandum & Articles of Association (copy of partnership deed in case of firm) with list of Directors/ partners/proprietor.

(p) The bidder shall submit certificate from the concernedLicensing Authority of approved formulations alongwithmanufacturing license approved by Licensing Authority.

(q) If the manufacturing licence(s) is under renewal, it should be confirmed from records and from enclosed documentary evidence by the party that application was made within time frame as per Act, , as amended from time to time.

(r) A certified copy of latest GMP certificate issued by the State Licensing Authority showing the GMP standards .

(s) A certified copy of registration certificate with central Govt. Health Scheme Govt. of India, Ministry of Health & Family Welfare.

(t) Attested copy of the two years Manufacturing & Marketing certificate issued by the State Licensing Authority of the product or similar products.

(u) Any document in the evidencing of the fact that bidder has rendered service as Marketing Associate for procuring orders from Govt. Institutions/ PSU& private sector.

(v) All the documents pertaining to offer should be signed by the bidder at the bottom of each page with the office seal/stamp duly affixed.

6. Earnest Money Deposits:

(a) The manufacturer shall furnish an earnest money of Rs. 2.00 lacs (Rupees Two Lacs only) alongwith the offer documents in the shape of Bank Draft in favour of "Rajasthan Drugs & Pharmaceuticals Ltd.", payable at Jaipur whichshall be kept in a separate envelop superscribing as “EARNEST MONEY DEPOSIT” and should be submitted alongwith offer documents in a Cover, failing which the offer is liable to be rejected.

(b) The earnest money deposit shall be liable to be forfeited in following circumstances:
   i. If the party fails to enter into Agreement after award of contract in his favour within 10 days.
   ii. If the party fails to follow any of the conditions of Agreement after award of contract.

7. Contract Conditions:

(a) Payment to such **Bidder(s)**will be made within 15 days from the date of receipt of realization from the Govt. Agency/Indenting Authority by RDPL, Jaipur against such specific business.The successful **Bidder(s)** will have to assist in getting payments from the concerned institution and shall complete the required formalities as per terms and conditions of the order of the institution.

(b) The quoted rate will be FOR RDPL Jaipur or destination provided by the RDPL.

(c) The Shelf life of the finished products will be based on the stability & bioavailability studies of the finished product submitted by the bidder:

8. Ratification and withdrawal of Offers:

(a) The bidder may withdraw or submit an addenda to his offer before the offers are opened.

(b) Once the offer documents are opened, no addition or alteration shall be allowed. Further, no party shall be allowed to withdraw his offer till the date of expiry of the validity of the offer.

9. **Opening of Offers:**
(a) The manufacturer representatives having may in evidence of attend offer opening and those who are present shall sign a Register their attendance.
(b) In the event of the specified date of offer opening being declared a Holiday for RDPL; the offers shall be opened at the aforesaid time on the next working day.

10. **Contract Award Criteria**:

RDPL shall award the contract to the successful party whose offer has been determined to be substantially responding in conformity with the conditions of offerand has been determined as the lowest evaluated offer, provided further that the party is determined to be qualified to perform the contract satisfactorily. A manufacturer with capability of rendering services as Marketing Associate shall be preferred.

11. **Rights to Accept or Reject any Offer:**
RDPL reserves the right to accept or reject any offer and to annul the bidding process and reject all bids at any time prior to award of contract without thereby incurring any liability to the affected party or any obligation to inform the affected party or any obligation to inform the affected on the grounds for RDPL's action.

12. **Agreement:**
The successful party shall have to sign an Agreement on Non-judicial stamp paper of adequate value as per stamp requirement of Govt. of Rajasthan for the successful completion of contract within 15 days of the award of contract.

13. **Security Deposits:**
The successful party shall be required to furnish a Bank Guarantee of 5% of total value of contract towards security deposit for successful performance of contract. The Bank Guarantee should be issued by a Nationalized Bank and same shall be retained by RDPL till the final fulfillment of the contract with validity for entire period of agreement plus expiry period of the product manufactured and supply & shall remain valid for a period of 60 days beyond the late of completion of all contractual obligations.

14. **Invocation of Bank Guarantee:**

The bank guarantee shall be invoked by RDPL:

I. If the party fails to provide manufacturedthe quality product within prescribed period.

II. If the supplier fails to replace the product within prescribed period where any supplies are found to be of inferior or sub standard quality.

III On any other ground as deemed fit by RDPL

15. **Inspections & tests for control over quality of products manufactured**

(a) RDPL or its representative shall have the right to inspect and or to test the goods in conformity with the specified specifications at no extra cost to RDPL.

(b) The inspections and test of the goods produced shall be conducted on the premises of bidder before dispatching the goods. The bidder shall make all reasonable testing facilities/ assistance available to the inspection team.

16. **Packing:**
The bidder shall assist to provide such packing of the goods as is required to prevent their damage or deterioration during transit and for safe delivery to

their final destination. The packing shall be sufficient to withstand, without limitation rough handling during transit and open storage. Packing case size and weights shall be taken into consideration, where appropriate, the remoteness of the final destination and the absence of heavy handling at all points in transit.

The packing, marking and documentation within and outside the packages shall comply strictly with such special requirements as shall be provided for in the contract including additional requirements, if any, as given by RDPL.

17. **Insurance:**

The goods supplied under the contract shall be fully insured for 110% value of the goods in Indian Rupee against any loss or damages, etc. in course of transit and shall be born by bidder.

18. **Delay in the supplies:**

(a) Delivery of the items / goods shall be made by the supplier within 30 days or in accordance with the conditions of the contract/work order at the time (s) and at the place (s) and in the manner specified in the tender documents and schedules and the orders to be placed. The supplier shall comply with the instructions of RDPL from time to time regarding safe transit of the goods.

(b) Any delay by the supplier in the performance of its delivery obligations shall render the supplier liable to imposition of liquidated damages, unless an extension of time is agreed upon with or without the application of liquidated damages. The quantum of liquidated damages to be recovered from the supplier shall be equivalent to the amount RDPL pays to its purchaser of goods because of the delayed supplies and/or non-supplies thereof.

(c) In case of abnormal delays, RDPL may cancel the contract or a portion thereof without entertaining any claim for compensation and, if so desired, purchase the stores not so delivered or other of a similar description at the risk and cost of the supplier.

(d) RDPL shall forfeit the security deposit furnished by the contractor supplier by way of invoking Bank Guarantee in the event of delay in supply, short delivery, non-supply or any kind of breach of contract under all circumstances.

(e) Where Tenderer fails to make supplies within stipulated period, RDPL is at liberty to make alternative purchase of items of drugs & medicines (for which the purchase orders have been placed) from any other source or open market at the cost and risk of Tenderer and in such cases RDPL has every right to recover the higher cost and and other charges incurred and impose penalty as prescribed elsewhere in this Tender document.

(f) The Tenderer shall take back drugs which are not utilized by RDPL within the shelf life period based on mutual agreement.

19 **Force-Majeure:**

(a) The party shall not be liable for forfeiture of its performance security, liquidated damages or termination for defaults if any to the extent that its delay in performance or other failure to perform its obligations under the contract is the result of any events of force-majeure.

(b) For purposes of this bid the clause "FORCE-MAJEURE" means an event beyond the control of the party and not involving the bidder's fault or negligence and not foreseeable. Such event may include wars or revolutions, fires, floods, epidemics, quarantine restrictions and freights embargoes etc. However such events do not include the power cut, and labour dispute.

(c) If a force-majeure situation arises, the party shall promptly notify RDPL in writing of such causes. Unless otherwise directed by RDPL in writing, the party shall continue to perform its obligation under the contract as far as practicable and shall seek all reasonable alternative means for performance not prevented by the force-majeure events.

20. **Termination of Contract:**

(a) RDPL by written notice sent to the bidder under Registered A.D. post may terminate the contract in whole or in part, at any time for its convenience. The notice of termination shall specify that termination is for RDPL's convenience, the extent to which performance of the party under the contract is terminated and the date on which such termination becomes effective.

(b) In case the party becomes bankrupt or otherwise insolvent, RDPL may at any time terminate the contract by giving written notice under Registered A.D. post to the party. In this event termination will be without compensation to the party, provided that such termination will not prejudice or affect any right or action or remedy which has accrued or will accrue there after to RDPL.

21. **Arbitration and resolution of disputes:**

(a) In the event of any question, dispute or difference arising under these conditions in connection with the contract, same shall be referred to Arbitration of an arbitrator to be nominated by MD, RDPL. The Arbitration and Conciliation Act, 1996 shall not be applicable to the arbitrations under this clause. The award of the arbitrator shall be binding upon parties to the dispute.

(b) Any disputes arising out of this contract shall be decided by the Courts at Jaipur Jurisdiction only.

22. Payment:

Payment will be made within 15 days from the date of receipt of realization from the Govt. Agency/Indenting Authority by RDPL, Jaipur.

23. **Validity:**

This contract shall remain in force for a oneyear from the date of signing of Agreement between RDPL and the party. The agreement can be further extended on mutual consent of both the parties.

24. **Deviation:**

The party shall submit a deviation Statement in case the offer is submitted contrary to the terms and conditions of the bid.

The bidder is required to sign the biddocuments and submit the same along with his proposal as a token of his acceptance to the terms and conditions of the Tender document. Technical Bid should be submitted in sealed envelopeduly marked on as "Technical Bid" may be kept in one sealed envelop marked as **"Tender document for manufacturing and supply of Pharmaceuticals Formulation"** and should be addressed to The Factory Manager at the above mentioned address. **Please note that only Price Quotation has to be given in the "Financial Bid" and all other documents are to be furnished in the "Technical Bid".**

Thus, sealedoffer with all documents / certifications and earnest money deposit (EMD) of Rs. 2.0 lac (through demand draft in favour of this company payable at Jaipur) should **be sent to the Factory Manager so as to reach this office latest by 15days from date of publication in the leading NEWS paper before 3.00pm.**

Technical Bid of the Offers received shall be opened on same day at 3.30 P.M in presence of available representatives of the bidders.

TheTechnical Committee notified by the competent Authority of RDPL for secrutiny of technical bids will shortlist the qualifying bidders based on the qualifying conditions and parameters of performance specified in the Tender document.

Financial Bid will be opened only of those bidders qualifying in technical bid.
For any further information please contact Manager-Material at any of telephone numbers 0141-4107102,4101708 between 2.00 PM to 4.30 PM on any working day.

Amendment(s)/Modification(s) to the said Tender document. If any, will be notified in our website www.rdpl-india.inonly and the bidders are advised to visit our website regularly to comply with the same before submission. Bids received in-complete form and/or after scheduled date will not be accepted& rejected outrightly.

Due date and time of submission of Tender document:
On or before15days from date of publication in the leading NEWS paper before 3.00pm.

The party shall submit a check list / Index of the documents in seriatum manner.
In case of due date for submission of Tender document being declared as Holiday for RDPL, the due date for submission of Tender document and opening of the same will be the next working day at the specified time. Tender document received shall be opened on same day in presence of available representatives of the bidders. For any information please contact at any telephone numbers 0141-4107109 between 10:00 AM to 4:30 PM on any working day.

For, Rajasthan Drugs & Pharmaceuticals Limited,

Factory Manager

(On Rs. 100/- Non-Judicial Stamp Paper)

Annexure – II

1. GUARANTEE CERTIFICATE / AFFIDAVIT

I, _____ (Designation _____ for and on behalf of M/s. _____ hereby declare that the drugs & formulations manufactured for Rajasthan Drugs & Pharmaceuticals Limited (RDPL), Road No.12, V.K.I. Area, Jaipur – 302 013 shall be of the best quality and strictly in accordance with the specifications prescribed in Annexure-I and we hereby guarantee to the purchaser that the said medicines would continue to conform to the description and quality aforesaid till the date of expiry from the date of manufacture of the said medicines and that notwithstanding the fact that the purchaser / inspector may have inspected and / or said medicines be discovered not to conform to the description and quality aforesaid, or have deteriorated (and the decision of the RDPL in that behalf will be final and conclusive), RDPL will be entitled to reject the said medicines, or such portion there of as may be discovered not to conform to the said description and quality. On such rejection, the said medicines will be at the supplier's risk and all provisions herein contained relating to the rejections of medicines. shall apply. The supplier shall, if so called upon to do, replace the medicines lying in the stock with RDPL free of cost at the ultimate destination, within a maximum period of two months or such further period as may be extended from time to time by RDPL in its discretion on application in writing made thereof by the supplier. In such event, the above-mentioned warranty period shall apply to the medicines replaced from the date of the replacement there of. Otherwise, the supplier shall pay to the purchaser such damages as may arise by reasons of the breach of the conditions herein on that behalf under this contract or otherwise. For substandard quality of medicines already consumed by the time that results are known, the supplier is liable to a penalty to the extent of the value of such items consumed which will be further determined at the sole discretion of the purchaser, in addition to any other penalty liable to be in imposed under the relevant law.

For and on behalf of _____

Signature

Name

Designation

Witness
Notary Public

Annexure – III

2. MANUFACTURING & MARKETING CERTIFICATE

This is to certify that M/s. _____ are holding valid Manufacturing Licence No. _____ date _____ of the State and they are manufacturing the following drugs & formulations for the last three years.

It is further certified that the following products are also being marketed for the last three years.

The products are as follows:

S.No.	Name of Products	Specifications as per IP

Note: This certificate is to be signed by the Drug Controller or Licensing Authority. Certificate issued by inspector of Drugs / Drug Inspector will not be accepted unless their authorization by the State Drug Controller to this effect is supported by documentary proof.

ANNEXURE - I

S No.	Name of the Products	Specification	Strength	Packing	Final Packing	%Assay AQL
•	Tab. Albendazole	IP	Each uncoated tablet contains Albendazole IP 400 mg.	20x50's in amber PVDC blister	20x50's in white E- flute cartons & 5 ply c/Box	NLT 98.5%
•	Tab. Albendazole	IP	Each uncoated tablet contains Albendazole IP 400 mg.	1's amber PVC blister		NLT 98.5%
•	Tab. Amoxycillin+Clavulanic Acid	IP	Each Tab. Amoxycillin 500mg+Clavulanic Acid 125mg.	1x6	10x6	
•	Tab Ciprofloxacin (Film coated)	IP	Each film-coated tablet contains Ciprofloxacin Hcl IP eq. To Ciprofloxacin 250mg	20x50's in amber PVDC blister	20x50's in white E- flute cartons & 5 ply c/Box	NLT 98.5%
•	Tab Ciprofloxacin (Film coated)	IP	Each film-coated tablet contains Ciprofloxacin Hcl IP eq. To Ciprofloxacin 500mg	25x20's in amber PVDC blister	25x20's in white E- flute cartons & 5 ply c/Box	NLT 98.5%
•	Tab. Ranitidine (Film coated)	IP	Each film-coated tablet contains Ranitidine Hydrochloride IP Eq.to Ranitidine 150 mg	10's Al/Al Strips	10x10's in white E- flute cartons & 5 ply c/Box	NLT 98.5%
•	Tab. Norfloxacin & Tinidazole (Film coated)		Each film-coated tablet contains Norfloxacin IP 400 mg Tinidazole IP 600mg	10x10's in amber PVDC blister	10x10's in white E- flute cartons & 5 ply c/Box	NLT 98.5%
•	Tab. Paracetamol 500 mg	IP	Each uncoated tablet contains Paracetamol IP 500 mg	20x50's in white PVC blister	20x50's in white E- flute cartons & 5 ply c/Box	NLT 98.5%
•	Tab. Antacid (Chewable)	NFI	Each uncoated tablet contains Dried Aluminium Hydroxide 250mg Magnesium Hydroxide 250 mg Methylpolysiloxane 50mg	25x40's in white PVC blister	25x40's in white E- flute cartons & 5 ply c/Box	NLT 98.5%
•	Cap. Amoxycillin	IP	Each Hard Gelatin capsule contains Amoxycillin Trihydrate IP equivalent to Amoxycillin 250 mg	20x50 clear PVDC Blister	20x50's in white E- flute cartons & 5 ply c/Box	NLT 98.5%
•	Cap. Amoxycillin	IP	Each Hard Gelatin Capsule Contains Amoxycillin Trihydrate IP equivalent to Amoxycillin 500 mg	25x20 clear PVDC Blister	25x20's in white E- flute cartons & 5 ply c/Box	NLT 98.5%
•	Cap. Doxycycllin	IP	Each Hard Gelatin Capsule Contains Doxycyclin Hydrochloride IP equivalent to Doxycyclin 100 mg	20x50 clear PVDC Blister	20x50's in white E- flute cartons & 5 ply c/Box	NLT 98.5%
•	Tab. Glimepiride	IP	Each Tab. 1mg. & 2mg.	10x10	10x10	
•	Tab. Metformin	IP	Each Tab. 250mg., 500mg. & 1000mg.	10x10	10x10	
•	Syrup Domperidone	IP	Each 5 ml contains Domperidone IP 5 mg	100 ml Amber coloured Glass / Pet Bottles	50 bottles in 5 ply C/ box	NLT 98.5%
•	Cap. Omeprazole	IP	Each Hard Gelatin Capsule Contains	20x50 clear PVDC	20x50's in white E- flute	NLT 98.5%

S No.	Name of the Products	Specification	Strength	Packing	Final Packing	%Assay AQL
			Omeprazole IP 20mg. (As Entric Coated Pellets)	Blister	cartons & 5ply c/Box	
•	Cap.Fluconazole		Each Hard Gelatin Capsule Contains Fluconazole BP 150mg	10x10 Al/ Al Strip	10x10's in white E- flute cartons & 5 ply c/Box	NLT 98.5%
•	Tab. Azithromycin	IP	Each Film Coated Tablet Contains Azithromycin Base 250mg (As Azithromycin Dihydrate IP)	20x50's in amber PVDC blister	20x50's in white E- flute cartons & 5 ply c/Box	NLT 98.5%
•	Tab. Azithromycin	IP	Each Film Coated Tablet Contains Azithromycin 500mg (As Azithromycin Dihydrate IP)	20x50's in amber PVDC blister	25x20's in white E- flute cartons & 5 ply c/Box	NLT 98.5%
•	Tab. Ofloxacin & Ornidazole		Each Film Coated Tablet Contains Ofloxacin IP 200mg Ornidazole IP 500mg	25x20's in amber PVDC blister	25x20's in white E- flute cartons & 5 ply c/Box	NLT 98.5%
•	Tab. Ofloxacin (Relox)	IP	Each Film Coated Tablet Contains Ofloxacin IP 200mg	20x50's amber PVDC blister	20x50's in white E- flute cartons & 5 ply c/Box	NLT 98.5%
•	Tab. Levofloxacin	IP	Each Film Coated Tablet Contains Levofloxacin Hemihydrate IP eq. to Levofloxacin 500mg	25x20's in amber PVDC blister	25x20's in white E- flute cartons & 5 ply c/Box	NLT 98.5%
•	Tab. Levofloxacin	IP	Each Film Coated Tablet Contains Levofloxacin Hemihydrate IP eq. to Levofloxacin 250mg	20x50's in amber PVDC blister	20x50's in white E- flute cartons & 5 ply c/Box	NLT 98.5%
•	Tab. Ciprofloxacin & Tinidazole		Each Film Coated Tablet Contains Tinidazole IP 600mg Ciprofloxacin IP 500mg (As Ciprofloxacin Hcl)	10x10's in amber PVDC blister	10x10's in white E- flute cartons & 5 ply c/Box	NLT 98.5%
•	Tab. Dicyclomine & Paracetamol		Each Uncoated Tablet Contains Dicyclomine Hcl IP 20mg Paracetamol IP 500mg	20x50's in white PVC blister	20x50's in white E-flutecartons & 5 ply c/Box	NLT 98.5%
•	Tab. Domperidone	IP	Each Uncoated Tablet Contains Domperidone Maleate IP eq. To Domperidone 10mg	20x50's amber PVDC blister	20x50's in white E- flute cartons & 5 ply c/Box	NLT 98.5%
•	Tab. Erythromycin	IP	Each Film Coated Tablet Contains Erythromycin Stearate IP Eq. to Erythromycin 250mg	20x50's in amber PVDC blister	20x50's in white E- flute cartons & 5 ply c/Box	NLT 98.5%
•	Tab. Erythromycin	IP	Each Film Coated Tablet Contains Erythromycin Stearate IP Eq. to Erythromycin 500mg	20x50's in amber PVDC blister	20x50's in white E- flute cartons & 5 ply c/Box	NLT 98.5%
•	Tab. Ibuprofen	IP	Each Film Coated Tablet Contains Ibuprofen IP 400mg	25x20's in amber PVDC blister	25x20's in white E- flute cartons & 5 ply c/Box	NLT 98.5%
•	Tab. Metronidazole	IP	Each Uncoated Tablet Contains Metronidazole IP 400mg	20x50's in white PVC blister	20x50's in white E-flutecartons & 5 ply c/Box	NLT 98.5%

S No.	Name of the Products	Specification	Strength	Packing	Final Packing	%Assay AQL
•	Tab. Metronidazole	IP	Each Uncoated Tablet Contains Metronidazole IP 200mg	20x50's in white PVC blister	20x50's in white E-flutecartons & 5 ply c/Box	NLT 98.5%
•	Tab. Norfloxacin	IP	Each Uncoated Tablet Contains Norfloxacin IP 400mg.	20x50's in amber PVDC blister	20x50's in white E- flute cartons & 5 ply c/Box	NLT 98.5%
•	Tab.Ranitidine	IP	Each Film Coated Tablet Contains Ranitidine Hydrochloride IP eq. to Ranitidine 300mg	10x10's Al/Al Strips	10x10's in white E- flute cartons & 5 ply c/Box	NLT 98.5%
•	Tab. Roxithromycin	IP	Each Film Coated Tablet Contains Roxithromycin IP 150mg	10x10's Al/Al Strips	10x10's in white E- flute cartons & 5 ply c/Box	NLT 98.5%
•	Tab. Roxithromycin	IP	Each Film Coated Tablet Contains Roxithromycin IP 300mg	10x10's Al/Al Strips	10x10's in white E- flute cartons & 5 ply c/Box	NLT 98.5%
•	Tab. Tinidazole	IP	Each Film Coated Tablet Contains Tinidazole IP 300mg	20x50's in amber PVDC blister	20x50's in white E- flute cartons & 5 ply c/Box	NLT 98.5%
•	Tab.Tinidazole	IP	Each Film Coated Tablet Contains Tinidazole IP 500mg.	20x50's in amber PVDC blister	20x50's in white E- flute cartons & 5 ply c/Box	NLT 98.5%
•	Oral Rehydration Salts	IP	Each Sachet Contains Sodium Chloride IP 2.6 gm Potassium Chloride IP 1.5gm Sodium Citrate IP 2.9 gm Dextrose Anhydrous 13.5gm	Al/Al /Paper Polyglassin Foil	4x100's 7 Ply C/box	NLT 98.5%
•	Tab. Nimesulide		Each Uncoated Tablet Contains Nimesulide BP 100mg.	20x50's in amber PVDC blister	20x50's in white E- flute cartons & 5 ply c/Box	NLT 98.5%
•	Tab. Cetirizine (Cetirizine Hcl)	IP	Each Uncoated Tablet Contains Cetirizine Hcl IP 10mg	20x50's in amber PVC blister	20x50's in white E- flute cartons & 5 ply c/Box	NLT 98.5%
•	Tab. Diclofenac Sodium 50mg	IP	Each Entric Coated Tablet Contains Diclofenac Sodium IP 50mg	20x50's in amber PVDC blister	20x50's in white E- flute cartons & 5 ply c/Box	NLT 98.5%
•	Cap. Cephalexin	IP	Each Hard Gelatin Capsule Contains Cephalexin IP eq. To Cephalexin (Anhydrous) 250mg	20x50's in Clear PVDC blister	20x50's in white E- flute cartons & 5 ply c/Box	NLT 98.5%
•	Cap. Cephalexin	IP	Each Hard Gelatin Capsule Contains Cephalexin IP eq. To Cephalexin (Anhydrous) 500mg	25x20's in Clear PVDC blister	25x20's in white E- flute cartons & 5 ply c/Box	NLT 98.5%
•	Cap. Omeprazole+Domeridon	IP	Each Cap. Omeprazole20mg. +Domeridon 10mg.	20x50	20x50	
•	Tab.Cefadroxil	IP	Each Uncoated Tablet Contains Cephadroxil IP eq. To Cefadroil (Anhydrous) 500mg	25x4's Al/Al Strips	25x4's in white E- flute cartons & 5 ply c/Box	NLT 98.5%

S No.	Name of the Products	Specification	Strength	Packing	Final Packing	%Assay AQL
•	Tab. Cefuroxim	IP	Each Film Coated Tablet Contains Cefuroxim Axetil IP eq. To Cefuroxim 250mg	25x4's Al/Al Strips	25x4's in white E- flute cartons & 5 ply c/Box	NLT 98.5%
•	Tab. Cefuroxim	IP	Each Film Coated Tablet Contains Cefuroxim Axetil IP eq. To Cefuroxim 500mg	25x4's Al/Al Strips	25x4's in white E- flute cartons & 5 ply c/Box	NLT 98.5%
•	Tab. Cephalexin Dispersible	IP	Each Dispersible Tablet Contains Cephalexin IP eq. To Cephalexin (Anhydrous) 125mg	20x50's in Amber PVDC blister	20x50's in white E- flute cartons & 5 ply c/Box	NLT 98.5%
•	Tab. Chloroquine	IP	Each Film Coated Tablet Contains Chloroquine Phosphate IP 250 mg eq. To 155mg chloroquine	20x50's in Milky white PVC blister	20x50's in white E- flute cartons & 5 ply c/Box	NLT 98.5%
•	Tab. Ibuprofen & Paracetamol		Each Uncoated Tablet Contains Ibuprofen IP 400mg Paracetamol IP 325mg	25x20's in Milky white PVC blister	25x20's in white E- flute cartons & 5 ply c/Box	NLT 98.5%
•	Tab. Ofloxacin	IP	Each Film Coated Tablet Contains Ofloxacin IP 400mg	20x50's in PVC Amber blister	20x50's in white E- flute cartons & 5 ply c/Box	NLT 98.5%
•	Tab. Ornidazole	IP	Each Film Coated Tablet Contains Ornidazole IP 500mg	25x20's in PVC Amber blister	25x20's in white E- flute cartons & 5 ply c/Box	NLT 98.5%
•	Tab. Diclofenac & Paracetamol		Each Uncoated Tablet Contains Paracetamol IP 500mg Diclofenac Sodium IP 50mg (As Enteric Coated Granules)	25x20's in Milky white PVC blister	25x20's in white E- flute cartons & 5 ply c/Box	NLT 98.5%
•	Syp. Kofeas C Expectorant		Each 5 ml Contains Chlorpheniramine Maleate IP 3mg Amonium Chloride IP 110mg Sodium Citrate IP 46mg Menthol IP 0.9mg	10ml Amber Coloured Bottle	50 bottles in 5 ply C/ box	NLT 98.5%
•	Syp. Kofeas Expectorant		Each 5 ml Contains Diphenhydramine Hcl IP 14mg Amonium Chloride IP 135mg Sodium Citrate IP 57mg Menthol IP 0.9mg	110ml Amber Coloured Bottle	50 bottles in 5 ply C/ box	NLT 98.5%
•	Tab Iron folic acid (Enteric coated)		Iron , folic Acid Large (WIFS)	10X15	10X15	NLT 98.5%
•	Tab Iron folic acid (Enteric coated)		Iron , folic Acid Small (WIFS)	10X15	10X15	NLT 98.5%
•	Tab Iron folic acid (Film coated)		Iron , folic Acid Large	10X15	10X15	NLT 98.5%
•	Tab Iron folic acid (Enteric coated)		Iron , folic Acid Small	10X15	10X15	NLT 98.5%
•	Sy Iron folic acid		Iron , folic Acid Large	100ml	100ml	NLT 98.5%
•	Sy Iron folic acid		Iron , folic Acid Small	100 ml	100 ml	NLT 98.5%
•	Susp. Albendazole		Each 5ml Contains Albendazole IP 200mg	10ml Amber Coloured Bottle	100 Vials in 5 ply C/ box	NLT 98.5%
•	Oint Betamethasone Valerate+Neomycin Sulp		Each Oint Betamethasone Valerate 0.12%+Neomycin Sulp 0.5%	20gm cream	20gm. Cream	NLT 98.5%
•	Oint Beclomethasone		Each Oint Beclomethasone Diprop.0.25%+Clotrimazole	15gm cream	15gm cream	NLT 98.5%

S No.	Name of the Products	Specification	Strength	Packing	Final Packing	%Assay AQL
	Diprop. +Clotrimazole		1%w/w			
•	Gel Diclofenac		Each Gel Diclofenac Diethylammonium Eqv. Sod. 1%, Methylisalicylate 8%, Monthol 2%	30gm.	30gm.	NLT 98.5%
•	Vitamin A Solution			50ml.	50ml.	NLT 98.5%
•	Calcium 250 mg+ Vit.D3		Calcium 250 mg+ Vit.D3/250ml.	25x20	25x20	NLT 98.5%
•	Calcium 500 mg+ Vit.D3		Calcium 500 mg+ Vit.D3/250ml.	25x20	25x20	NLT 98.5%
•	Co-trimoxazole I.P. (D.S.) (Trimethoprim I.P. 160 mg. +Sulphamethoxazole I.P. 800 mg.	IP	Co-trimoxazole I.P. (D.S.) (Trimethoprim I.P. 160 mg. +Sulphamethoxazole I.P. 800 mg.	10x10	10x10	NLT 98.5%
•	Co-trimoxazole I.P. (S.S.) (Trimethoprim I.P. 80 mg. +Sulphamethoxazole I.P. 400 mg.	IP	Co-trimoxazole I.P. (S.S.) (Trimethoprim I.P. 80 mg. +Sulphamethoxazole I.P. 400 mg.	10x10	10x10	NLT 98.5%
•	Oint Povidone Iodine		Oint Povidone Iodine 5%w/w	20gm	20gm.	NLT 98.5%
•	Solution Povidone Iodine		Solution Povidone Iodine 5%	100ml.	100ml.	NLT 98.5%
•	Poly Vitamin (Prop.)		Poly Vitamin (Prop.)	10x50	10x50	NLT 98.5%
•	Vitamin B-Complex (Prophy.)		Vitamin B- Complex (Prophy.)	10x50	10x50	NLT 98.5%
•	Tab. Cefixime		Each Tab. 100mg. & 200mg.	20x50	20x50	NLT 98.5%

Note:
Appropriate overages may please be added in antibiotics & vitamin preparations to compensate the losses on storage.
Our AQL limit should not less than 98.5% in any product. However manufacture must intent for 100% drug content of labeled claim.

Packing Specification

All Capsules and Moisture sensitive Tablets should be packed in PVDC / Alu, Alu/Alu, Blister/Strip
PVDC Specification : 250 + 60 micron
Unit pack should be packed in white E-Flute carton and followed by 5 Ply C/Box